MET and breast cancer: With submicromolar IC50 values against c-Met and VEGFR-2, the compound exhibited extraordinary dual inhibitory activity, demonstrating its capacity to concurrently disrupt two key signaling pathways associated with breast cancer angiogenesis, proliferation, and metastasis.